2389. Effect of Rezafungin on QT Interval in Healthy Subjects

BACKGROUND: Rezafungin (RZF), a novel, once-weekly echinocandin for treatment and prophylaxis of invasive fungal infections, successfully met safety and efficacy endpoints in Phase 2 and is advancing to Phase 3 studies. RZF is the first echinocandin to undergo a definitive QT evaluation. METHODS: Th...

Descripción completa

Detalles Bibliográficos
Autores principales: Flanagan, Shawn, Goodman, Daniel B, Rao, Pallavi, Jandourek, Alena, O’Reilly, Terry, Sandison, Taylor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2018
Materias:
Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255498/
http://dx.doi.org/10.1093/ofid/ofy210.2042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255498/
http://dx.doi.org/10.1093/ofid/ofy210.2042

Ejemplares similares